Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06104852 · ClinicalTrials.gov registry record
Triage Survey for Neurology Research Eligibility
A clinical trial of Alzheimer Disease, sponsored by Adams Clinical.
- Recruiting
- Registry status
- 600
- Enrollment target
- 3
- Study locations
NCT06104852 is a study of Alzheimer Disease that is actively recruiting participants, run by Adams Clinical. The registered enrollment target is 600 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06104852, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Adams Clinical.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 3
- Study locations
Study Summary
TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.
Conditions Studied
Interventions
- OTHER Survey
- OTHER Optional Medication Washout
Study Locations (3)
Massachusetts
- Copley Clinical - Boston
- Adams Clinical - Watertown
New York
- Berman Clinical - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-06-02 |
| Est. Completion | 2027-06-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06104852
The ClinicalTrials.gov registry entry for NCT06104852 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (78% lower). The listed sponsor is Adams Clinical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Survey is the first listed.
NCT06104852 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06104852 about?
NCT06104852 is a clinical study titled "Triage Survey for Neurology Research Eligibility". TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.
What is the current status of trial NCT06104852?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2023-06-02. Estimated completion is 2027-06-02.
What conditions does trial NCT06104852 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06104852?
The interventions under investigation include: Survey (OTHER), Optional Medication Washout (OTHER).
Who is sponsoring clinical trial NCT06104852?
This trial is sponsored by Adams Clinical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06104852 being conducted?
This trial has 3 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.